These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1280 related articles for article (PubMed ID: 29859173)

  • 1. Mesenchymal Stromal Cells: Clinical Challenges and Therapeutic Opportunities.
    Galipeau J; Sensébé L
    Cell Stem Cell; 2018 Jun; 22(6):824-833. PubMed ID: 29859173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mesenchymal Stromal Cells in Pediatric Hematopoietic Cell Transplantation a Review and a Pilot Study in Children Treated With Decidua Stromal Cells for Acute Graft-versus-Host Disease.
    Ringdén O; Gustafsson B; Sadeghi B
    Front Immunol; 2020; 11():567210. PubMed ID: 33193339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mesenchymal stromal cells: Putative microenvironmental modulators become cell therapy.
    Krampera M; Le Blanc K
    Cell Stem Cell; 2021 Oct; 28(10):1708-1725. PubMed ID: 34624232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenges and advances in clinical applications of mesenchymal stromal cells.
    Zhou T; Yuan Z; Weng J; Pei D; Du X; He C; Lai P
    J Hematol Oncol; 2021 Feb; 14(1):24. PubMed ID: 33579329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mesenchymal stromal cells for acute graft-versus-host disease: response at 1 week predicts probability of survival.
    Galleu A; Milojkovic D; Deplano S; Szydlo R; Loaiza S; Wynn R; Marks DI; Richardson D; Orchard K; Kanfer E; Tholouli E; Saif M; Sivaprakasam P; Lawson S; Bloor A; Pagliuca A; Potter V; Mehra V; Snowden JA; Vora A; Kishore B; Hunter H; Apperley JF; Dazzi F
    Br J Haematol; 2019 Apr; 185(1):89-92. PubMed ID: 30637732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Mesenchymal Stromal Cells From Different Origins for the Treatment of Graft-vs.-Host-Disease in a Humanized Mouse Model.
    Grégoire C; Ritacco C; Hannon M; Seidel L; Delens L; Belle L; Dubois S; Vériter S; Lechanteur C; Briquet A; Servais S; Ehx G; Beguin Y; Baron F
    Front Immunol; 2019; 10():619. PubMed ID: 31001253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gastro-intestinal autoimmunity: preclinical experiences and successful therapy of fistulizing bowel diseases and gut Graft versus host disease by mesenchymal stromal cells.
    Voswinkel J; Francois S; Gorin NC; Chapel A
    Immunol Res; 2013 Jul; 56(2-3):241-8. PubMed ID: 23564182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mesenchymal Stromal Cells for Enhancing Hematopoietic Engraftment and Treatment of Graft-Versus-Host Disease, Hemorrhages and Acute Respiratory Distress Syndrome.
    Ringdén O; Moll G; Gustafsson B; Sadeghi B
    Front Immunol; 2022; 13():839844. PubMed ID: 35371003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft-versus-host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition.
    Fisher SA; Cutler A; Doree C; Brunskill SJ; Stanworth SJ; Navarrete C; Girdlestone J
    Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009768. PubMed ID: 30697701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mesenchymal Stromal Cells for Graft Versus Host Disease: Mechanism-Based Biomarkers.
    Cheung TS; Bertolino GM; Giacomini C; Bornhäuser M; Dazzi F; Galleu A
    Front Immunol; 2020; 11():1338. PubMed ID: 32670295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mesenchymal stromal cells for the prophylaxis and treatment of graft-versus-host disease-a meta-analysis.
    Morata-Tarifa C; Macías-Sánchez MDM; Gutiérrez-Pizarraya A; Sanchez-Pernaute R
    Stem Cell Res Ther; 2020 Feb; 11(1):64. PubMed ID: 32070420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Follow-Up After the Application of Mesenchymal Stromal Cells in Children and Adolescents with Steroid-Refractory Graft-Versus-Host Disease.
    Döring M; Cabanillas Stanchi KM; Lenglinger K; Treuner C; Gieseke F; Erbacher A; Mezger M; Vaegler M; Schlegel PG; Greil J; Bettoni da Cunha Riehm C; Faul C; Schumm M; Lang P; Handgretinger R; Müller I
    Stem Cells Dev; 2021 Mar; 30(5):234-246. PubMed ID: 33446053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mesenchymal Stromal Cell Therapy for Chronic Lung Allograft Dysfunction: Results of a First-in-Man Study.
    Chambers DC; Enever D; Lawrence S; Sturm MJ; Herrmann R; Yerkovich S; Musk M; Hopkins PM
    Stem Cells Transl Med; 2017 Apr; 6(4):1152-1157. PubMed ID: 28186707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of mesenchymal stem cells in hematopoietic stem cell transplantation: prevention and treatment of graft-versus-host disease.
    Zhao L; Chen S; Yang P; Cao H; Li L
    Stem Cell Res Ther; 2019 Jun; 10(1):182. PubMed ID: 31227011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current perspectives on mesenchymal stromal cell therapy for graft versus host disease.
    Kadri N; Amu S; Iacobaeus E; Boberg E; Le Blanc K
    Cell Mol Immunol; 2023 Jun; 20(6):613-625. PubMed ID: 37165014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics and clinical applications of Wharton's jelly-derived mesenchymal stromal cells.
    Liau LL; Ruszymah BHI; Ng MH; Law JX
    Curr Res Transl Med; 2020 Jan; 68(1):5-16. PubMed ID: 31543433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alpha-1 Antitrypsin-Expressing Mesenchymal Stromal Cells Confer a Long-Term Survival Benefit in a Mouse Model of Lethal GvHD.
    Geiger S; Ozay EI; Geumann U; Hereth MK; Magnusson T; Shanthalingam S; Hirsch D; Kälin S; Günther C; Osborne BA; Tew GN; Hermann FG; Minter LM
    Mol Ther; 2019 Aug; 27(8):1436-1451. PubMed ID: 31138510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Children and Adults with Refractory Acute Graft-versus-Host Disease Respond to Treatment with the Mesenchymal Stromal Cell Preparation "MSC-FFM"-Outcome Report of 92 Patients.
    Bonig H; Kuçi Z; Kuçi S; Bakhtiar S; Basu O; Bug G; Dennis M; Greil J; Barta A; Kállay KM; Lang P; Lucchini G; Pol R; Schulz A; Sykora KW; Teichert von Luettichau I; Herter-Sprie G; Ashab Uddin M; Jenkin P; Alsultan A; Buechner J; Stein J; Kelemen A; Jarisch A; Soerensen J; Salzmann-Manrique E; Hutter M; Schäfer R; Seifried E; Paneesha S; Novitzky-Basso I; Gefen A; Nevo N; Beutel G; Schlegel PG; Klingebiel T; Bader P
    Cells; 2019 Dec; 8(12):. PubMed ID: 31817480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase I Study to Evaluate Two Doses of Wharton's Jelly-Derived Mesenchymal Stromal Cells for the Treatment of De Novo High-Risk or Steroid-Refractory Acute Graft Versus Host Disease.
    Soder RP; Dawn B; Weiss ML; Dunavin N; Weir S; Mitchell J; Li M; Shune L; Singh AK; Ganguly S; Morrison M; Abdelhakim H; Godwin AK; Abhyankar S; McGuirk J
    Stem Cell Rev Rep; 2020 Oct; 16(5):979-991. PubMed ID: 32740891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune effects of mesenchymal stem cells: implications for Charcot-Marie-Tooth disease.
    Leal A; Ichim TE; Marleau AM; Lara F; Kaushal S; Riordan NH
    Cell Immunol; 2008; 253(1-2):11-5. PubMed ID: 18627903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 64.